Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Special Report
  • Published:

Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

Bone Marrow Transplantation volume 49, pages 168–173 (2014)Cite this article

Subjects

A Corrigendum to this article was published on 23 December 2013

Abstract

GVHD remains the major impediment to broader application of allogeneic haematopoietic SCT. It can be prevented completely, but at the expense of other complications, rejection, relapse or delayed immune reconstitution. No optimal prevention or treatment method has been defined. This is reflected by enormous heterogeneity in approaches in Europe. Retrospective comparisons between different policies, although warranted, do not give definite answers. In order to improve the present situation, an European Group for Blood and Marrow Transplantation and the European LeukemiaNet working group has developed in a Delphi-like approach recommendations for prophylaxis and treatment of GVHD in the most common allogeneic transplant setting, transplantation from an HLA-identical sibling or unrelated donor for standard risk malignant disease. The working group proposes these guidelines to be adopted as routine standard in transplantation centres and to be used as comparator in systematic studies evaluating the advantages and disadvantages of practices differing from these recommendations.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Patterson J, Prentice HG, Brenner MK, Gilmore M, Janossy G, Ivory K et al. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol 1986; 63: 221–230.

    Article  CAS  PubMed  Google Scholar 

  2. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806–812.

    Article  CAS  PubMed  Google Scholar 

  3. Bacigalupo A, Van Lint MT, Occhini D, Guolandi F, Lamparelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–1428.

    CAS  PubMed  Google Scholar 

  4. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF, on behalf of the Chronic Leukaemia Working Party of the EBMT. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759–764.

    Article  CAS  PubMed  Google Scholar 

  5. Ruutu T, van Biezen A, Hertenstein B, Henseler A, Garderet L, Passweg J et al. Prophylaxis and treatment of graft versus host disease after haematopoietic stem cell transplantation: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47: 1459–1464.

    Article  CAS  PubMed  Google Scholar 

  6. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transransplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219–234.

    Article  CAS  PubMed  Google Scholar 

  7. Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A et al. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation and donor health. Bone Marrow Transplant 2008; 42: 9–14.

    Article  CAS  PubMed  Google Scholar 

  8. Halter JP, van Walraven SM, Worel N, Bengtsson M, Hägglund H, Nicoloso de Faveri G et al. Allogeneic hematopoietic stem cell donation: standardized assessment of donor outcome data—A WBMT consensus document. Bone Marrow Transplant 2012; 48: 220–225.

    Article  PubMed  Google Scholar 

  9. Ljungman P, Engelhard D, de la Camara R, Einsele H, Locasciulli A, Martino R et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005; 35: 737–746.

    Article  CAS  PubMed  Google Scholar 

  10. Zaia J, Baden L, Boeckh MJ, Chakrabarti S, Einsele H, Ljungman P et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44: 471–482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger A, Frere P et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 2011; 46: 709–718.

    Article  CAS  PubMed  Google Scholar 

  12. Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J et al. Introduction of a quality management system and outcome after hematopoietic stem cell transplantation. J Clin Oncol 2011; 29: 1980–1986.

    Article  PubMed  Google Scholar 

  13. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1150–1163.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-vs.-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

    Article  CAS  PubMed  Google Scholar 

  15. Gratwohl AA, Bull MI, Graw RG Jr, Norton L, Knutsen T . Methotrexate and citrovorum factor after histoincompatible allogeneic bone marrow transplants in dogs. Acta Haematol 1978; 60: 233–242.

    Article  CAS  PubMed  Google Scholar 

  16. Gratwohl A . Folinic acid administration following MTX as prophylaxis for GVHD. Bone Marrow Transplant 2009; 44: 257.

    Article  CAS  PubMed  Google Scholar 

  17. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560–565.

    Article  PubMed  Google Scholar 

  18. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomized, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855–864.

    Article  CAS  PubMed  Google Scholar 

  19. Thomas FT, Griesedieck C, Thomas J, Carver M, Whitley T, Warren R et al. Differential effects of horse ATG and rabbit ATG on T cell and T cell subset levels measured by monoclonal antibodies. Transplant Proc 1984; 16: 1561–1563.

    CAS  PubMed  Google Scholar 

  20. Mohty M . Mechanism of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387–1394.

    Article  CAS  PubMed  Google Scholar 

  21. Penack O, Fischer L, Gentilini C, Nogal A, Muessig A, Rieger K et al. The type of ATG matters—natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius. Transplant Immunol 2007; 18: 85–87.

    Article  CAS  Google Scholar 

  22. Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007; 109: 3219–3224.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Atta EH, Dias DS, Marra VL, de Azevedo AM . Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia; a single-center study. Ann Hematol 2010; 89: 851–859.

    Article  CAS  PubMed  Google Scholar 

  24. Hatanaka K, Fuji S, Ikegame K, Kato R, Wake A, Hidaka M et al. Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin. Int J Hematol 2012; 96: 773–780 Erratum in: Int J Hematol 2013; 97: 154-155.

    Article  CAS  PubMed  Google Scholar 

  25. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Storb R . Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia? Leukemia 2001; 15: 662–663.

    Article  CAS  PubMed  Google Scholar 

  27. Niederwieser D, Maris M, Shizuru J, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remission in patients with hematological diseases. Blood 2003; 101: 1620–1629.

    Article  CAS  PubMed  Google Scholar 

  28. Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scime R, Locatelli F et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288–2293.

    CAS  PubMed  Google Scholar 

  29. Van Lint MT, Milone G, Leotta S, Uderzo C, Scime R, Dallorso S et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006; 107: 4177–4181.

    Article  CAS  PubMed  Google Scholar 

  30. Martin PJ, Inamoto Y, Flowers MED, Carpenter PA . Secondary treatment of acute graft-versus-host disease: a critical review. Biol Blood Marrow Transplant 2012; 18: 982–988.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Filipovich AH, Weisdorf D, Pavletic S, Socié G, Wingard JR, Lee SJ et al. National Institute of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  32. Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16: 1611–1628.

    Article  PubMed  Google Scholar 

  33. Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Bone Marrow Transplant 2011; 17: 1–17.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

    T Ruutu

  2. Hematology, Medical Faculty, University of Basel, Basel, Switzerland

    A Gratwohl

  3. Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

    T de Witte

  4. R. Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, St Petersburg State Medical I.P.Pavlov University, St Petersburg, Russia

    B Afanasyev

  5. Department of Haematology, Hammersmith Hospital, Imperial College London, London, UK

    J Apperley

  6. Division of Hematology, IRCCS San Martino, Genova, Italy

    A Bacigalupo

  7. Department of Medicine, Imperial College London, Hammersmith Campus, London, UK

    F Dazzi

  8. Department of Medicine V, University of Heidelberg, Heidelberg, Germany

    P Dreger

  9. Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain

    R Duarte

  10. Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany

    J Finke

  11. Service d’Hematologie, Hôpital Saint Antoine, Paris, France

    L Garderet

  12. Department of Internal Medicine I, Medical University, Vienna, Austria

    H Greinix

  13. Department of Haematology/Oncology, University Hospital Regensburg, Regensburg, Germany

    E Holler

  14. Department of Stem Cell Transplantation, University Cancer Centre Hamburg, Hamburg, Germany

    N Kröger

  15. St Anna Children’s Hospital, Vienna, Austria

    A Lawitschka

  16. Service d’Hématologie Clinique et de Thérapie Cellulaire, Hopital Saint Antoine, Universite Pierre et Marie Curie, INSERM, Paris, France

    M Mohty

  17. Hematology Division, Tel-Aviv University, Sheba Medical Center, Tel-Hashomer, Israel

    A Nagler

  18. Center for Stem Cell Transplantation, University Hospital Basel, Basel, Switzerland

    J Passweg

  19. Center for Allogeneic Stem Cell Transplantation, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden

    O Ringdén

  20. Department of Hematology—Transplantation, Saint-Louis Hospital, Paris, France

    G Socié

  21. Haematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    J Sierra

  22. Haematology Department, Addenbrookes Hospital, Cambridge, UK

    A Sureda

  23. Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland

    W Wiktor-Jedrzejczak

  24. Anthony Nolan Research Institute, Royal Free Hospital, London, UK

    A Madrigal

  25. Department of Hematology/Oncology and Hemostasiology, University of Leipzig, Leipzig, Germany

    D Niederwieser

Authors
  1. T Ruutu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Gratwohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T de Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Afanasyev
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Apperley
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Bacigalupo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Dazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Duarte
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. L Garderet
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H Greinix
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E Holler
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A Lawitschka
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A Nagler
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. J Passweg
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. O Ringdén
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. G Socié
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. J Sierra
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. A Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. W Wiktor-Jedrzejczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. A Madrigal
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. D Niederwieser
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

a working group of the European Group for Blood and Marrow Transplantation (EBMT) and the European LeukemiaNet (ELN)

Corresponding author

Correspondence to T Ruutu.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruutu, T., Gratwohl, A., de Witte, T. et al. Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice. Bone Marrow Transplant 49, 168–173 (2014). https://doi.org/10.1038/bmt.2013.107

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.107

Keywords

This article is cited by

Search

Advanced search

Quick links